CARL ZEISS MEDITEC AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.8 EUR | +0.46% |
|
-2.49% | -1.05% |
| Apr. 24 | CARL ZEISS MEDITEC AG : Gets a Buy rating from UBS | ZD |
| Apr. 23 | CARL ZEISS MEDITEC AG : Receives a Sell rating from JP Morgan | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Sales forecast by analysts have been recently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 33.47 and 26.41 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 4.12 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -1.05% | 9.42B | B+ | ||
| +7.84% | 218B | B | ||
| +7.35% | 184B | B- | ||
| +13.04% | 135B | B- | ||
| +26.03% | 107B | A- | ||
| -1.33% | 62.38B | A- | ||
| +11.80% | 51.37B | B+ | ||
| +4.81% | 50.9B | B+ | ||
| +0.30% | 40.87B | A | ||
| +2.78% | 36.28B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AFX Stock
- Ratings Carl Zeiss Meditec AG
